TrianglePUBLICATIONS · 22363068
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Oncologist
- Publication date
- 2012
- First author
- Fox E
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Fox E
- type
- Author
- name
- Patel S
- type
- Author
- name
- Wathen JK
- type
- Author
- name
- Schuetze S
- type
- Author
- name
- Chawla S
- type
- Author
- name
- Harmon D
- type
- Author
- name
- Reinke D
- type
- Author
- name
- Chugh R
- type
- Author
- name
- Benjamin RS
- type
- Author
- name
- Helman LJ
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Fox E
- type
- Author
- name
- Patel S
- type
- Author
- name
- Wathen JK
- type
- Author
- name
- Schuetze S
- type
- Author
- name
- Chawla S
- type
- Author
- name
- Harmon D
- type
- Author
- name
- Reinke D
- type
- Author
- name
- Chugh R
- type
- Author
- name
- Benjamin RS
- type
- Author
- name
- Helman LJ
- type
- Author
- bibliography ids
- nci-bib-13d5b52f4ea2459fdf6f7223
- book metadata
- content sha256
- c8b590fdcd24a27b96acb19e84180508f2081bcbb15d0bb68aa7a6135636e7b3
- document type
- citation
- dois
- 10.1634/theoncologist.2010-0265
- electronic publication date
- display
- 2012 Feb 23
- precision
- day
- year
- 2012
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:22363068
- immutable id
- pubmed:22363068@c8b590fdcd24a27b96acb19e84180508f2081bcbb15d0bb68aa7a6135636e7b3
- journal
- abbreviation
- Oncologist
- issn electronic
- 1549-490X
- issn print
- 1083-7159
- issue
- 3
- name
- The oncologist
- nlm unique id
- 9607837
- pages
- 321
- volume
- 17
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 22363068
- provenance
- batch id
- b6284687e167e7da9556
- provider
- NCBI PubMed ESummary
- record sha256
- 97e27a94d7f1c25d7935a60374f6eb2297a00ba7747981fec33471cba79810d9
- response sha256
- 64d5b7bb63f574c559af2523b779a262267cbc8e8cd02a5b47f4193cc95cabd3
- retrieved at
- 2026-09-09T23:46:45.216259+00:00
- publication date
- display
- 2012
- precision
- year
- year
- 2012
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Preserved source evidence · Not medical advice